Iseganan

CAS No: 257277-05-7

Purity: 95%

Molar Mass: 1900.28

Chemical Formula: C78H126N30O18S4

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Product Name: Iseganan

CAS No: 257277-05-7

Purity: 95%

Molar Mass: 1900.28

Chemical Formula: C78H126N30O18S4

Synonyms: IB-367

Storage: Store at -20℃

Sequence: RGGLCYCRGRFCVCVGR

Target: antibacterial

Application: Iseganan (CAS: 257277-05-7) is a synthetic antimicrobial peptide that has demonstrated potent activity against a wide range of Gram-positive and Gram-negative bacteria, as well as fungi. It works by disrupting microbial cell membranes, leading to cell lysis and death. Iseganan has shown promise in the treatment of various infections, including oral mucositis, a common complication of chemotherapy and radiation therapy in cancer patients. Its topical formulation allows for direct application to affected mucosal surfaces, where it can exert its antimicrobial effects while minimizing systemic exposure and potential side effects. Clinical trials have indicated that iseganan may help reduce the severity and duration of oral mucositis and improve patients’ quality of life during cancer treatment. Additionally, iseganan’s low propensity for inducing resistance makes it an attractive option for the management of multidrug-resistant infections. Despite its potential benefits, further research is needed to optimize dosing regimens, evaluate long-term safety, and explore additional therapeutic indications for iseganan. Overall, iseganan represents a promising antimicrobial agent with the potential to address unmet medical needs in the treatment of infectious diseases and oral mucositis.

Reference: Elad, S., Epstein, J. B., Raber‐Durlacher, J., Donnelly, P., & Strahilevitz, J. (2012). The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double‐blind, placebo‐controlled, randomized, phase III clinical trial. Journal of oral pathology & medicine, 41(3), 229-234.